Even in the era of pneumococcal conjugate vaccination, this risk is nearly doubled.
The incidence of invasive pneumococcal disease (IPD), although much reduced since vaccination against Streptococcus pneumoniae was introduced, continues to be a leading cause of morbidity and mortality worldwide. Previous studies in children with asthma have shown an elevated risk for IPD but were conducted before pneumococcal conjugate vaccine was introduced.
To assess the risk for IPD in children with asthma after introduction of pneumococcal conjugate vaccine, researchers conducted a meta-analysis of data from four observational studies (three industry-funded) in children from birth to age 18 years. Vaccination in the study populations was mostly with the 7-valent pneumococcal conjugate vaccine (PCV7).
The pooled risk estimate revealed tha…
Reviewing Author
DisclosuresGrant/Research SupportNIH Institutional Clinical and Translational Science Award; Agency for Healthcare Research and Quality National Center for Pediatric Practice Based Research Learning; Patient-Centered Outcomes Research Institute
Editorial BoardsCurrent Problems in Pediatric Adolescent Healthcare
Leadership Positions in Professional Societies College of Physicians of Philadelphia (Board of Trustees)
DisclosuresGrant/Research SupportNIH Institutional Clinical and Translational Science Award; Agency for Healthcare Research and Quality National Center for Pediatric Practice Based Research Learning; Patient-Centered Outcomes Research Institute
Editorial BoardsCurrent Problems in Pediatric Adolescent Healthcare
Leadership Positions in Professional Societies College of Physicians of Philadelphia (Board of Trustees)